抑制补体C5a或C5aR对胆固醇结晶栓塞相关血管血栓形成及微血管损伤的作用
胆固醇结晶栓塞(CCE)涉及免疫血栓形成、组织坏死和器官衰竭,目前无特异性治疗。本研究在小鼠肾动脉注射胆固醇微晶体,发现数小时内出现肾内免疫血栓,24小时后肾小球滤过率骤降和缺血性肾坏死;遗传性C3或C5aR缺陷及预防性抑制C5a或C5aR均可阻止上述后果,延迟C5a阻断仍能溶解结晶血栓并预防所有后果。
要点
- 抑制C5a或C5aR可预防胆固醇结晶栓塞相关的免疫血栓和肾缺血坏死。
- 延迟C5a阻断仍能溶解已形成的结晶血栓并阻止后续后果。
- 高风险患者预防性抑制C5a/C5aR可能具有临床可行性和安全性。
核心结论
- 选择性阻断C5a或C5aR足以减轻已建立的胆固醇结晶栓塞的后果。
研究设计与样本
- 野生型小鼠肾动脉注射胆固醇微晶体建立CCE模型,观察数小时至24小时的免疫血栓、肾小球滤过率变化和缺血性肾坏死。
主要发现
- 注射胆固醇微晶体后数小时内出现肾内免疫血栓,24小时后肾小球滤过率骤降和缺血性肾坏死。
- 遗传性C3或C5aR缺陷可预防免疫血栓、肾小球滤过率下降和24小时缺血性坏死。
- 预防性抑制C5a或C5aR同样可预防上述后果。
- 延迟C5a阻断在晶体注射后仍能溶解结晶血栓并预防所有后果。
临床怎么用
- 选择性阻断C5a或C5aR可能用于减轻已建立的胆固醇结晶栓塞后果。
- 高风险患者预防性抑制C5a/C5aR可能具有临床可行性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cholesterol crystal embolism (CCE) implies immunothrombosis, tissue necrosis, and organ failure but no specific treatments are available. As CCE involves complement activation, we speculated that inhibitors of the C5a/C5aR axis would be sufficient to attenuate the consequences of CCE like that with systemic vasculitis. Cholesterol microcrystal injection into the kidney artery of wild-type mice initiated intra-kidney immunothrombosis within a few hours followed by a sudden drop of glomerular filtration rate and ischemic kidney necrosis after 24 hours. Genetic deficiency of either C3 or C5aR prevented immunothrombosis, glomerular filtration rate drop, and ischemic necrosis at 24 hours as did preemptive treatment with inhibitors of either C5a or C5aR. Delayed C5a blockade after crystal injection still resolved crystal clots and prevented all consequences. Thus, selective blockade of C5a or C5aR is sufficient to attenuate the consequences of established CCE and prospective inhibition in high-risk patients may be clinically feasible and safe.
引用
- Zhao D, Han C, Mammadova-Bach E, et al. Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism-related vascular thrombosis with microvascular injury and its consequences. Kidney Int. 2024. PMID: 39142565. doi:10.1016/j.kint.2024.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。